|Home | About | Journals | Submit | Contact Us | Français|
The epidermal growth factor receptor (EGFR) contributes to tumor radioresistance, in part, through interactions with the catalytic subunit of DNA-dependent Protein Kinase (DNA-PKcs), a key enzyme in the non homologous end joining DNA repair pathway. We previously demonstrated that EGFR-DNA-PKcs interactions are significantly compromised in the context of activating mutations in EGFR in non small cell lung carcinoma (NSCLC) and human bronchial epithelial cells. Here, we investigate the reciprocal relationship between phosphorylation status of DNA-PKcs and EGFR-mediated radiation response. The data reveal that both the kinase activity of DNA-PKcs and radiation-induced phosphorylation of DNA-PKcs by the Ataxia Telangiectasia Mutated (ATM) kinase are critical prerequisites for EGFR-mediated radioresponse. Alanine substitutions at 7 key serine/threonine residues in DNA-PKcs or inhibition of DNA-PKcs by NU7441 completely abrogated EGFR-mediated radioresponse and blocked EGFR binding. ATM-deficiency or ATM inhibition with KU55933 produced a similar effect. Importantly, alanine substitution at an ATM-dependent DNA-PKcs phosphorylation site, T2609, was sufficient to block binding or radioresponse of EGFR. However, mutation of a DNA-PKcs auto-phosphorylation site, S2056 had no such effect indicating that DNA-PKcs auto-phosphorylation is not necessary for EGFR-mediated radioresponse. Our data reveal that in both NSCLCs and HBECs, activating mutations in EGFR specifically abolished the DNA-PKcs phosphorylation at T2609, but not S2056. Our study underscores the critical importance of a reciprocal relationship between DNA-PKcs phosphorylation and EGFR mediated radiation response and elucidates mechanisms underlying mutant EGFR associated radiosensitivity in NSCLCs.
The epidermal growth factor receptor (EGFR), a 170 kDa receptor tyrosine kinase, is an important determinant of tumor resistance to ionizing radiation (IR) in a number of cancers including non-small cell lung cancer (NSCLC). In addition to cell proliferation, (1–3) and apoptosis inhibition (4, 5), EGFR has a direct role in the repair of IR-induced double strand breaks (DSB) (6) and (reviewed in (7, 8)).
Evidence from a number of laboratories shows that, in response to IR, EGFR is rapidly internalized and translocates to the nucleus (9–11). Moreover, nuclear EGFR has been shown to interact with the catalytic and regulatory subunits of the DNA-dependent protein kinase (DNA-PK) in an IR-dependent manner (6, 9). The precise domains in EGFR and DNA-PK that are involved in this interaction are not known.
DNA-PK plays an important role in the non homologous end joining DNA repair pathway (NHEJ). It is composed of the regulatory DNA binding heterodimer, Ku70/80, and a catalytic subunit, DNA-PKcs. Ku70/80 heterodimer binds broken DNA ends of DSBs. Two molecules of DNA-PKcs are then recruited to the DNA break (12). In response to radiation, DNA-PKcs is rapidly activated and phosphorylated at several serine and threonine residues which are organized into distinct clusters (13). These clusters include the 2609 (or ABCDE) cluster (14, 15), the 2056 (or PQR) cluster (16) and a C’ terminal site (17, 18). IR-induced serine 2056 (S2056) auto-phosphorylation (19) is mediated by DNA-PKcs itself, but the phosphorylation of many residues in the 2609 and 2056 clusters, particularly threonine 2609 (T2609), is mediated by the Ataxia Telangiectasia Mutated kinase (ATM) (20). The auto-phosphorylation of the 2609 cluster promotes end-processing (13), notably through the activity of the Artemis endonuclease (21), while the auto-phosphorylation at the 2056 cluster inhibits end processing and promotes ligation of DNA ends (16). Both DNA-PKcs S2056 auto-phosphorylation and ATM-mediated T2609 phosphorylation appear to be essential for DNA-PKcs-mediated DSB repair and radioresistance (20). Whether the phosphorylation status of DNA-PKcs affects EGFR-mediated radiation response is not known.
Somatic activating mutations in EGFR have been clinically linked to dramatic responses in NSCLC patients to the EGFR inhibitors, gefitinib and erlotinib (22–25). We previously demonstrated that NSCLCs harboring either an in-frame deletion (ΔE746-E750) in the 19th exon or an leucine to arginine substitution (L858R) in the 21st exon of the EGFR tyrosine kinase domain exhibit dramatic sensitivity to IR (26). Moreover, ectopic expression of L858R or ΔE746-E750 EGFR in different NSCLC cells lines or HBEC cells significantly reduced cellular radioresistance in a dominant negative manner (26). We showed that mutant EGFR associated radiosensitivity manifests as pronounced delays in repair of IR induced DSBs, inhibition of IR-induced nuclear translocation and absence of IR-induced EGFR-DNA-PKcs interactions (27). However, how mutant EGFR expression affects DNA-PKcs activity and function is not fully understood.
Here, we ectopically express wild type, L858R and ΔE746-E750 forms of EGFR and evaluate their relative contributions to clonogenic survival in the genetic background of various site-specific, phospho-ablating mutations in DNA-PKcs. We interrogate key DNA-PKcs residues for their ability to modulate IR-induced interactions between EGFR and DNA-PKcs and support EGFR-mediated radiation response. Our search reveals that IR-induced phosphorylation of T2609 in DNA-PKcs is a critical requirement for this interaction. Surprisingly, T2609 phosphorylation is also under the influence of EGFR. Our data support a model in which EGFR modulates DNA-PKcs function through stabilization of T2609 phosphorylation.
The NSCLC cell lines, NCI-A549, NCI-H820, NCI-HCC827 and NCI-H1975 were from the American Type Culture Collection (ATCC). The immortalized Human Bronchial Epithelial (HBEC) cell line was originally obtained from John D. Minna (UT Southwestern Medical center) (28). All cell lines were maintained as previously described (27). CHO cell lines,V3-7A, V3-WT DNA-PKCS, V3-S2056A and V3-T2609A, and fibroblast cell lines, 1BR3, and AT5, were a generous gift from Dr. David J. Chen and were maintained as previously described (20, 29). The wild-type EGFR, L858R, and ΔE746-E750 forms of EGFR were tagged with V5 epitope in lentiviral vectors through recombinational cloning using the Gateway system (Invitrogen/Gibco-BRL, Carlsbad, CA). Immortalized HBEC or CHO cell lines, were genetically modified by lentivirus infection of V5-tagged EGFR forms or an unrelated LacZ construct and maintained as previously described (28, 30).
Clonogenic survival was measured as described before (26, 27). Where inhibitors were used, cells received a 2 h pretreatment with vehicle, 10 µM NU7441, or KU55933 prior to irradiation and were plated at various densities 8 h later (delayed plating). Mean SF was plotted as a function of radiation dose from ≥3 independent experiments, each performed in triplicate samples per dose. Curves were fitted to the linear quadratic equation.
EGFR was immunoprecipitated using an anti-EGFR antibody (Clone R19/48, Biosource,44-796G) and DNA-PKcs and EGFR were detected by Western blot (WB) using anti-DNA-PKcs, and EGFR antibodies as described previously (27). Phosphorylated ATM was detected by WB assay using p-ATM antibody (p-S1981, 200-301-400, Rockland Inc,) and blots were stripped and re-probed with ATM antibody (5C2, GeneTex).
Stable complexes of EGFR and DNA-PKcs or PP2A and DNA-PKcs were detected using the Duolink® proximity ligation assay (PLA) kit according to the manufacturer’s instructions (Olink Bioscience, Uppsala, Sweden). NSCLC or HBEC cells expressing wild type, L858R and ΔE746-E750 mutant EGFR were exposed to 4 Gy IR. For inhibition experiments, cells were pretreated for 2 h prior to IR with 10 µM of NU7441 or KU55933. At various time points, cells were fixed for immunofluorescence staining as described before (27) and simultaneously incubated with mouse DNA-PKcs antibody (Clone 25-4, Lab Vision, dilution 1:150) and rabbit anti-EGFR antibody (Santa Cruz, sc-03, 1:1000) or rabbit anti-PP2A antibody (Clone 81G5, Cell Signaling, S2041, 1:100 dilution). Cells were incubated with complementary oligonucleotide-conjugated anti-rabbit and anti-mouse secondary antibodies followed by ligation and rolling circle amplification in the presence of a Texas Red conjugated nucleotide. The fluorescent amplicons manifest as red fluorescent dots, with each dot representing a specific and stable interaction between the two interacting proteins. Cells were co-stained with 4',6-Diamidino-2-phenylindole (DAPI) and images were acquired using Zeiss Axiophot fluorescence microscope with a 40× objective. After correcting for illumination, integrated fluorescence intensity of foci in 600–800 nuclei per experiment was measured using the Cell profiler image analysis software (31). Mean integrated fluorescence intensity per nucleus and standard error of means from ≥3 independent experiments was used to quantify EGFR-DNA-PKcs or PP2A-DNA-PKcs binding at various time points following IR.
DNA-PKcs phosphorylation in response to 4 Gy IR was measured by staining formalin fixed, Triton-X-100-permeabilized cells with antibodies against pT2609 or S2056 (20) which were detected by Alexa-488-conjugated secondary antibodies. Images were acquired using a 40× objective of the Zeiss Axiophot fluorescence microscope. After correcting for illumination, integrated fluorescence intensity of phospho DNA-PKcs per nucleus in 450–600 nuclei per experiment was measured using the Cell profiler image analysis software (31). Mean integrated fluorescence intensity per nucleus and standard error of means from ≥2 independent experiments were reported.
To examine the effect of DNA-PKcs phosphorylation on wild type or mutant EGFR-mediated radiation responses, we stably expressed the wild type, L858R, or ΔE746-E750 forms of EGFR in three different DNA-PKcs backgrounds: DNA-PKcs-deficient V3 CHO cells, V3 cells stably expressing wild type human DNA-PKcs (V3-WT) or V3 cells stably expressing a catalytically active, but DSB-repair defective, mutant form of human DNA-PKcs (V3-7A) in which 7 alanine replacements in the 2609 and 2056 clusters (Figure 1A and B). Consistent with previous observations (27), in V3-WT DNA-PKCS cells, ectopic expression of wild type EGFR significantly increased clonogenic survival, whereas expression of the L858R and ΔE746-E750 activating mutant forms of EGFR had a pronounced dominant-negative radiosensitizing effect relative to untransfected cells (Figure 1C, middle). This contrasting pattern of radiation responses associated with wild type and mutant EGFR expression was completely abrogated in V3 cells (Figure 1C, left) or V3-7A cells (Figure 1C, right). The data indicate EGFR-mediated radiation response is not only DNA-PKcs-dependent but also requires phosphorylation of residues in the 2056 and 2609 clusters of DNA-PKcs.
Previous reports have shown that IR-induced phosphorylation of many of the residues in the 2056 and 2609 cluster of DNA-PKcs is ATM-dependent (20). To test whether ATM-deficiency has any effect on EGFR mediated effects on cellular radiosensitivity, we over-expressed wild type, L858R, or ΔE746-E750 forms of EGFR in ATM-proficient, 1BR3, or ATM-deficient, AT5, backgrounds (Figure 2A). The data in Figure 2B show that both wild type EGFR-mediated radioprotection and mutant EGFR-mediated radiosensitization are intact in 1BR31 cells. In AT5 cells, on the other hand, expression of either wild type or mutant EGFR did not significantly affect clonogenic survival relative to mock- or LacZ-transfected cells. The data indicate that IR-induced ATM-driven DNA-PKcs phosphorylation is an essential requirement for EGFR-mediated radiation response.
A key step in EGFR-mediated radiation response requires binding of EGFR and DNA-PKcs which is abrogated by activating mutations, L858R or ΔE746-E750 in EGFR (27) and supplemental figure, S1C. We first tested whether phospho-ablating mutations in 7A-DNA-Pkcs affected EGFR binding. Figure 3A shows that in V3-WT cells, interactions between wild type DNA-PKcs and wild type EGFR occurred as early as 5 minutes following 4 Gy IR, persisted until 90 minutes and diminished shortly thereafter. As expected, WT DNA-PKcs failed to co-precipitate with L858R or the ΔE746-E750 mutant form of EGFR (27). Interestingly, the 7A mutant form of DNA-PKcs was undetectable in immune complexes of wild type or mutant EGFR. The data indicate that alanine substitution in 7 of the 11 phosphorylation sites in DNA-PKcs completely abolished radiation-induced binding of EGFR. We reasoned that the reported abrogation of DNA-PKcs phosphorylation in the context of ATM-deficiency (20) should similarly affect EGFR-DNA-PKcs binding. As expected, DNA-PKcs co-precipitated with wild type EGFR (Figure 3B) in ATM-proficient 1BR31 fibroblast cells but such interaction was undetectable in ATM-deficient AT5 cells even at 90 minutes following IR. The data indicate that radiation-induced interactions between EGFR and DNA-PKcs are dependent, in part, on ATM-driven phosphorylation of DNA-PKcs.
We next examined whether EGFR-mediated radioresponses and radiation-induced EGFR-DNA-PKcs binding are dependent on the kinase activity of DNA-PKcs or ATM. NU7441 (2-N-morpholino-8-dibenzothiophenyl-chromen-4-one) and KU55933 (2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one) are highly potent, selective inhibitors of DNA-PKcs and ATM respectively (32, 33). In HBEC cells, a 2 hour pre-treatment with either NU7441 or KU55933 completely abolished the survival responses associated with both wild type and mutant EGFR (Figure 4A). Moreover, NU7441 or KU55933 pretreatment completely eliminated IR-induced associations between DNA-PKcs and EGFR in co-immunoprecipitation assays (Figure 4B). To quantify the effects of NU7441 or KU55933 on EGFR-DNA-PKcs binding in NSCLCs and HBEC we used the proximity ligation assay (PLA). PLA relies on in situ detection of protein-protein interactions through a fluorescent signal which is generated only when two interacting proteins are physically associated with each other. PLA not only allows the quantitative assessment of protein-protein interactions but also reveals the sub-cellular location where they predominate. Figure 4C shows that in wild type EGFR expressing A549 cells, relative to untreated cells, at 1 hour following 4 Gy IR, there was a significant (12.5-fold) increase in EGFR-DNA-PKcs complexes, occurring predominantly in the nuclear region of the cells. Both basal and radiation-induced PLA fluorescence was undetectable in the ΔE746-E750 expressing H820 cells. More importantly, NU7441 or KU55933 treatment completely abrogated both basal and radiation-induced EGFR-DNA-PKcs complexes in A549 cells and showed no appreciable change over baseline in H820 cells. In the isogenic settings of HBEC cells (Figure 4C, bottom panel), NU7441 or KU55933 pre-treatment similarly eliminated the ~200-fold IR-induced increase in EGFR-DNA-PKcs associations in wild type EGFR expressing HBEC cells. By contrast, cells expressing the ΔE746-E750 EGFR showed no such increase and were not further affected by treatment with either inhibitor. The data indicate that kinase activities of both, DNA-PKcs and ATM, are critical for the radiation-induced binding of DNA-PKcs and EGFR in NSCLCs and HBEC.
Previous studies demonstrate that radiation-induced phosphorylation of DNA-PKcs at T2609 in the 2609 cluster is ATM-dependent while S2056 is auto-phosphorylated by DNA-PKcs in an ATM-independent manner (20). Our next objective was to examine whether alanine substitution at either of these residues would affect EGFR-DNA-PKcs binding and in turn alter EGFR-mediated survival responses. Towards this end, we stably expressed wild type and mutant EGFR in V3 cells expressing either a S2056A-mutated (V3-S2056A) or T2609A-mutated (V3-T2609A) forms of DNA-PKcs (Figure 5A). V3-S2056A cells were more radiosensitive compared to V3-T2609A cells (Figure 5B). However, only V3-S2056A cells exhibited the characteristic decrease in radiosensitivity associated with wild type EGFR and increase in radiosensitivity typical of L858R or ΔE746-E750 EGFR. By contrast, survival of V3-T2609A cells was strikingly unresponsive to wild type or mutant EGFR expression, indicating that T2609 was crucial in supporting EGFR-mediated survival response to radiation. We compared IR-induced binding of EGFR with S2056A or T2609A mutant forms of DNA-PKcs. In V3-S2056A cells we observed a robust 40-fold IR-induced increase in nuclear complexes of EGFR and the S2056A mutant DNA-PKcs (Figure 5C). In V3-T2609A cells, however, IR-induced complexes between EGFR and the T2609A mutant DNA-PKcs were virtually undetectable. Co-immunoprecipitiation assay essentially confirmed these findings in Figure 5D. The data in Figure 5 offer compelling evidence that DNA-PKcs phosphorylation at T2609, but not S2056 is critical for radiation-induced EGFR-DNA-PKcs binding and EGFR-mediated radioresponses.
Radiation-induced EGFR-DNA-PKcs interactions are absent in cells expressing the L858R or ΔE746-E750 mutant forms of EGFR (Figure 3A and (27)). We investigated whether this had any effect on the phosphorylation status of DNA-PKcs. We used an immune-fluorescence microscopy approach to quantify the extent and sub-cellular location of DNA-PKcs phosphorylation. We focused on two specific residues. Phosphorylation of T2609 is ATM-dependent, whereas S2056 is auto-phosphorylated by DNA-PKcs in an ATM-independent manner (20). Figure 6A shows that, in wild type EGFR expressing HBEC cells, DNA-PKcs phosphorylation at both, T2609 and S2056 rapidly increased in response to 4 Gy. Cells expressing the L858R or ΔE746-E750 forms of EGFR, showed a similar IR-induced increase in S2056 phosphorylation. Surprisingly, IR-induced DNA-PKcs phosphorylation at T2609 was virtually undetectable even at 60 minutes following IR. The data indicate that mutant EGFR expression specifically abrogates radiation-induced phosphorylation of DNA-PKcs at T2609 but not S2056.
We next verified the relationship between EGFR mutation status and T2609 phosphorylation in NSCLC cell lines. Exposure of wild type expressing A549 NSCLC to 4 Gy resulted in a ~1000-fold increase in DNA-PKcs phosphorylation at T2609 (Figure 6C). Both basal and radiation-induced DNA-PKcs phosphorylation was undetectable in the L858R expressing H1975 cells or the ΔE746-E750 expressing H820 cells. However, HCC827, which also harbors the ΔE746-E750 mutant, exhibited a ~75-fold increase in T2609 phosphorylation with radiation, although this was dramatically lower than the ~1000-fold increase observed in A549 NSCLCs. Moreover, while IR-induced T2609 phosphorylation in A549 cells was NU7441-insensitive, but KU55933-sensitive, IR-induced T2609 phosphorylation in HCC827 NSCLC cells was unaffected by either ATM- or DNA-PKcs-inhibition, indicating a mechanism unrelated to ATM or DNA-PKcs.
The data in Figure 6 indicate that activating mutations in EGFR adversely influence radiation-induced phosphorylation of DNA-PKcs at T2609. We considered two possibilities. First, we examined whether mutant EGFR directly influences DNA-PKcs p-T2609 though an ATM-dependent mechanism. Results in Figure 7A and 7B indicate that in both NSCLCs and HBEC cells, L858R or ΔE746-E750 expression had no effect on overall ATM levels or ATM phosphorylation at S1981. Second, we examined whether wild type or mutant EGFR expression had any effect on interactions between DNA-PKcs and the protein phosphatase, PP2A. There is evidence that radiation-induced DNA-PKcs phosphorylation is regulated by protein phosphatase PP2A which de-phosphorylates and inactivates DNA-PKcs (34). Data in Figure 7C and 7D demonstrate that in un-irradiated A549 and wild type EGFR expressing HBEC cells, levels of PP2A-DNA-PKcs interactions predominate but are significantly reduced (~3-fold) on exposure to 4 Gy IR. In striking contrast, ΔE746-E750 mutant EGFR expressing H820 and HBEC cells have higher basal levels of PP2A-DNA-PKcs complexes and exposure to IR resulted in a further (≥2-fold) increase in PP2A-DNA-PKcs binding. The data provide compelling evidence that activating mutations in EGFR significantly augment PP2A-DNA-PKcs interactions and suggest a possible mechanism underlying mutant EGFR-associated abrogation of T2609 phosphorylation.
The data so far indicate that EGFR mediates survival response to radiation through IR-induced interactions with DNA-PKcs which are abrogated in a dominant negative manner in the context of radiosensitizing L858R or ΔE746-E750 EGFR mutations. Our study demonstrates for the first time that DNA-PKcs phosphorylation is an essential prerequisite for EGFR-DNA-PKcs interaction. Alanine substitutions in DNA-PKcs that prevent its radiation-induced phosphorylation abrogate EGFR-DNA-PKcs binding (Figures 3A, 5C and 5D). Of these, the T2609A and S2056A mutations are particularly relevant. Evidence shows that p-T2609 is an ATM-dependent phosphorylation event, whereas p-S2056 is an ATM-independent DNA-PKcs auto-phosphorylation event (20). Our data indicate that p-T2609 is a site of interaction between DNA-PKcs and EGFR because T2609A, but not S2056A, substitution abrogated EGFR binding (Figures 5C and 5D). Moreover, ATM deficiency (Figure 2) or inhibition (Figure 4), which abrogates T2609 (Figure 6C), but not S2056 phosphorylation (20), also blocked EGFR-DNA-PKcs binding. DNA-PKcs or ATM alterations had no effect on IR-induced EGFR nuclear translocation (Supplemental figures, S1A–S1C) suggesting a direct impact on nuclear EGFR-DNA-PKcs interaction.
Both, DNA-PKcs-7A and T2609A, mutants are catalytically active but do not bind EGFR (Figures 3A and and5D).5D). Moreover, alanine substitution at S2056, a substrate of DNA-PKcs kinase activity, did not affect EGFR-DNA-PKcs binding (Figures 5C and 5D). However, DNA-PKcs inhibition by NU7441 completely inhibited EGFR-DNA-PKcs binding (Figure 4B) raising the possibility that other DNA-PKcs auto-phosphorylation sites could be involved.
Surprisingly, in addition to its pivotal role in EGFR-DNA-PKcs binding, T2609 phosphorylation is also influenced by EGFR. Our study demonstrates for the first time, that activating mutations in EGFR specifically inhibit IR-induced phosphorylation of DNA-PKcs at T2609, but not S2056, a pattern that closely resembles EGFR blockade by anti-EGFR antibody, C225 (9, 35) or ATM inhibition by KU55933 (Figure 6 and (20)). At least with mutant EGFRs, the mechanism is likely ATM-independent, because IR-induced ATM S1981 phosphorylation (Figures 7A and 7B) was not affected.
Our data reveal an inverse relationship between EGFR-DNA-PKcs binding and DNA-PKcs association with protein phosphatase, PP2A. Wild-type EGFR expression was associated with dramatic IR-induced increases in EGFR-DNA-PKcs binding, corresponding reductions in PP2A-DNA-PKcs complexes and robust IR-induced DNA-PKcs-T2609 phosphorylation. By contrast, in both basal and IR-induced settings, mutant EGFR expression was associated with absence of EGFR-DNA-PKcs complexes (Figure 3A), significantly elevated levels of PP2A-DNA-PKcs complexes (Figure 7C and 7D) and abrogation of IR-induced DNA-PKcs-T2609 phosphorylation (Figure 6). However, PP2A phosphorylation at Y307 (Figure 7E, bottom panel) or EGFR-PP2A binding (Figure 7E, top panel) was unaffected by radiation or EGFR mutation status. Thus, EGFR modulates radiation response predominantly through interactions with DNA-PKcs which likely stabilizes DNA-PKcs phosphorylation.
Mutant EGFR-associated abrogation of T2609 phosphorylation has important implications on DNA-PKcs function. Studies show that DNA-PKcs phosphorylation at different sites govern either the stability of the DSB-DNA-PKcs complex required for end processing, or the timely dissociation of DNA-PKcs, which appears critical for DNA end ligation (14, 16, 37, 38). Uematsu et al observed that wild type and T2609A-mutated DNA-PKcs had similar kinetics of association or dissociation at DSBs (29). We observed no change in the dissociation kinetics of wild type DNA-PKcs with L858R or ΔE746-E750 mutant EGFR expression (data not shown). Two groups have shown that phosphorylation of the 2609 cluster in DNA-PKcs plays a critical role in regulating the intra-strand endonuclease activity of the Artemis nuclease (21, 39). It is therefore conceivable that mutant EGFR-mediated inhibition of p-T2609 adversely influences Artemis activity and DNA end-processing.
Our study proffers important insights on EGFR’s contribution to cellular radiosensitivity. In V3-WT DNA-PKcs cell, effects of L858R or ΔE746-E750 mutant EGFR expression (Figures 1C, middle) on radiosensitivity were not as dramatic compared to DNA-PKcs ablation (Figure 1C, left) or NU7441 inhibition (Figure 4A, middle). This is logical because DNA-PKcs has multiple roles in DSB repair and cellular radioresistance, only some of which may be EGFR-dependent. Nagasawa et al recently demonstrated that, relative to wild type DNA-PKcs, single T2609A or S2056A mutations exhibit modest radiosensitivity, whereas a T2609A/S2056A double mutation has a synergistic effect on radiosensitivity (36). The synergism of the T2609A/S2056A double mutation suggests that p-T2609 and p-S2056 govern distinct, non-overlapping functions of DNA-PKcs. Our study reveals that at least one of these non-overlapping DNA-PKcs functions, pT2609, is modulated by EGFR. Wild type or mutant EGFR effects on radiosensitivity were evident in the S2056A, but not T2609A, genetic background. Moreover, L858R or ΔE746-E750 expression had a strikingly similar radiosensitizing effect on V3-S2056A cells (Figure 5B, left) as the T2609A/S2056A double mutation (36).
Our study underscores a modulatory role for EGFR in DSB repair and radiation resistance. In its simplest form, our model suggests that initial IR-induced, ATM-dependent DNA-PKcs phosphorylation at T2609 is a prerequisite for the binding of nuclear EGFR to DNA-PKcs. This association adversely affects PP2A-DNA-PKcs interactions and stabilizes DNA-PKcs-T2609 phosphorylation, which is critical for Artemis-mediated DSB end possessing. Activating mutations in EGFR prevent EGFR-DNA-PKcs interaction, favor DNA-PKcs-PP2A association and compromise p-T2609 stability which adversely affects DSB processing. Our study has important implications on how radiotherapy in combination with EGFR blockade may benefit NSCLC patients, especially those that harbor radioresistant tumors with wild type EGFR.
This study was funded by NIH/NCI grant CA129364 (CN) and the Simmons Comprehensive Cancer Center Bridge funds (CN).
Conflict of Interest: NONE. The authors of this manuscript have no conflicts of interest.